Related Experiment Video
Updated: Oct 18, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
Long-Term Recurrence of Completely Resected NSCLC
Katsuhiro Masago1, Katsutoshi Seto1,2, Shiro Fujita1
1Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
JTO Clinical and Research Reports
|September 30, 2021
Summary
Late recurrence in early-stage non-small cell lung cancer (NSCLC) is linked to driver mutations. Postoperative surveillance beyond five years may benefit patients with these genetic alterations.
Area of Science:
- Oncology
- Thoracic Surgery
- Molecular Diagnostics
Background:
- Early-stage non-small cell lung cancer (NSCLC) requires understanding of late recurrence patterns.
- Identifying clinical factors associated with recurrence beyond five years post-surgery is crucial for patient management.
Purpose of the Study:
- To investigate the clinical characteristics, particularly driver mutations, of early-stage NSCLC patients experiencing recurrence more than five years after resection.
Main Methods:
- A cohort of 512 patients with surgically resected NSCLC was analyzed.
- Patients underwent curative surgery between 2006 and 2011 at Aichi Cancer Center Hospital.
Main Results:
- 32.8% of patients (172/512) experienced recurrence post-surgery.
- A significant proportion (94.1%, 16/17) of late recurrences (beyond 5 years) were associated with driver mutations, including gene rearrangements.
Conclusions:
- Late recurrence ( >5 years) can occur even in early-stage NSCLC after complete resection.
- The high prevalence of driver mutations in late-recurrent cases suggests their role in disease progression.
- Extended postoperative surveillance may be warranted for early-stage NSCLC patients with identified driver mutations.
Related Concept Videos
01:27Pneumothorax-II
475
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
475
02:40Cancer Stem Cells and Tumor Maintenance
5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K